Latent EBV impairs immune cell signaling and enhances the efficacy of anti-CD3 mAb in Type 1 Diabetes.
Lledo Delgado, A.; Preston-Hurlburt, P.; Lim, N.; Sumida, T. S.; Long, S. A.; McNamara, J.; Serti, E.; Higdon, L.; Herold, K. C.
Show abstract
Teplizumab has been approved for the delay of the onset of type 1 diabetes and may modulate new onset disease. We found that patients who were EBV positive at baseline had a more robust response to drug in two clinical trials and therefore postulated that latent virus has general effects in modifying immune responses. We compared the phenotypes, transcriptomes, and development of peripheral blood cells before and after teplizumab treatment. Higher number of Tregs and partially exhausted CD8+ T cells were found in EBV seropositive individuals at the baseline in the TN10 trial and AbATE trial. Single cell transcriptomics and functional assays identified downregulation of the T cell receptor and other signaling pathways before treatment. Impairments in function of adaptive immune cells were enhanced by teplizumab treatment in EBV seropositive individuals. Our data indicate that EBV can impair signaling pathways generally in immune cells, that broadly redirect cell differentiation.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events 92%
- CD155 blockade enhances allogeneic natural killer cell-mediated antitumor response against osteosarcoma 92%
- Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy 92%
Similar papers in this journal
- COVID-19 convalescents exhibit deficient humoral and T cell responses to variant of concern Spike antigens at 12 month post-infection 94%
- Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4 and BA.5 in patients receiving monoclonal antibodies 93%
- Rewired type I IFN signaling is linked to age-dependent differences in COVID-19 92%
Similar papers in this journal
- Impact of multiple sclerosis disease-modifying therapies on SARS-CoV-2 vaccine-induced antibody and T cell immunity 93%
- Insights into the Absence of Lymphoma Despite Fulminant Epstein-Barr Virus Infection in Patients with XIAP Deficiency 93%
- Immunogenic epitope panel for accurate detection of non-cross-reactive T cell response to SARS-CoV-2 92%
Similar papers in this journal
- Prolonged T-cell activation and long COVID symptoms independently associate with severe disease at 3 months in a UK cohort of hospitalized COVID-19 patients 93%
- Preexisting memory CD4 T cells in nÏave individuals confer robust immunity upon hepatitis B vaccination 93%
- Regulatory T cells suppress the formation of potent KLRK1 and IL-7R expressing effector CD8 T cells by limiting IL-2 92%
Similar papers in this journal
- BCR, not TCR, repertoire diversity is associated with favorable COVID-19 prognosis 94%
- Specific induction of double negative B cells during protective and pathogenic immune responses 93%
- Antigenic determinants of SARS-CoV-2-specific CD4 + T cell lines reveals M protein-driven dysregulation of interferon signaling 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.